The Bayer Schering Pharma (BSP) Contraceptive Security Initiative seeks to address the ever increasing need for access to an affordable contraceptive in the developing world while recognizing the ever decreasing amount of donor funding available. As the first ever project of this nature, BSP will register, market and promote Microgynon Fe, an oral contraceptive, at an affordable price to middle income women in multiple developing countries on a continuous and permanent basis. BSP will seek to create a permanent market niche for Microgynon Fe as a “tier 2” product. As such, Microgynon Fe will have a price point above the social marketing and public sector level and below commercial prices, thus insuring its sustainability beyond USAID funding. As a long-term commitment to USAID, BSP has committed to maintaining this price point over time.